Engineered cell therapies, methods of administration thereof and methods of monitoring thereof
A controlled administration and monitoring approach using engineered immunoresponsive cells with specific cytokine release and chimeric antigen receptors addresses the challenges of unregulated armoring in cell-based therapies, improving anti-tumor immunity and reducing tumor volume effectively.
WO2026136971A1PCT designated stage Publication Date: 2026-06-25SENTI BIOSCI INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- SENTI BIOSCI INC
- Filing Date
- 2025-12-19
- Publication Date
- 2026-06-25
Smart Images
Figure US2025060796_25062026_PF_FP_ABST
Abstract
Described herein are multicistronic expression systems that encode chimeric proteins, specifically membrane-cleavable chimeric systems and chimeric antigen receptors for administration in combination with the cytokine IL2 for treating a subject having cancer. Also described herein are nucleic acids, cells, and methods directed to the same. Also described herein are methods of stimulating a cell-mediated immune response to a tumor, reducing tumor volume, or providing an anti-tumor immunity in a human subject in need thereof, the methods comprise administering to a subject multiple administrations of an immunoresponsive cell encoding a controlled release cytokine.
Need to check novelty before this filing date? Find Prior Art